A 3-month open-label, randomized, multicenter, phase IV trial investigated the effect of topical 3% diclofenac in 2.5% hyaluronic acid gel in 65 patients with actinic keratoses. Complete clinical resolution was seen in 16.9% (n = 11) and complete histological resolution in 23.1%. The number of mitoses, and those expressing anti-p53 and anti-MiB-1 antibodies all significantly decreased. Diclofenac in hyaluronic acid gel appears to be a promising treatment option for regression of actinic keratoses cancerous transformation (Dirschka, T. et al. JEADV 2010, 24(3): 258).